Telix Pharmaceuticals Limited (TLX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $12.59 (+0.68%), Market cap $3.54B, 52-week low–high $6.41 ~ $18.70.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem c
Financial statements, price targets, institutional (13F) holdings and related news for Telix Pharmaceuticals Limited are updated in real time on BlackAll Trade.
Telix Pharmaceuticals Limited trades at $12.59 (+0.68%). Real-time quotes and charts are available on BlackAll Trade.
Telix Pharmaceuticals Limited has a market cap of about $3.54B.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates t